Clinical Trial: Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (>= 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07080905) titled 'Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (>= 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B' on July 07.

Brief Summary: This is a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B.

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: Hemophilia B

Intervention: GENETIC: CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua)

Administered as a single IV infusi...